MX2023006786A - Anticuerpos inmunomoduladores biespecificos que se fijan a receptores coestimuladores y de puntos de control. - Google Patents

Anticuerpos inmunomoduladores biespecificos que se fijan a receptores coestimuladores y de puntos de control.

Info

Publication number
MX2023006786A
MX2023006786A MX2023006786A MX2023006786A MX2023006786A MX 2023006786 A MX2023006786 A MX 2023006786A MX 2023006786 A MX2023006786 A MX 2023006786A MX 2023006786 A MX2023006786 A MX 2023006786A MX 2023006786 A MX2023006786 A MX 2023006786A
Authority
MX
Mexico
Prior art keywords
immunomodulatory antibodies
checkpoint receptors
bind costimulatory
bispecific immunomodulatory
bispecific
Prior art date
Application number
MX2023006786A
Other languages
English (en)
Inventor
Gregory Moore
John Desjarlais
Matthew Bernett
Christine Bonzon
Michael Hedvat
Umesh S Muchhal
Zhenyu Shen
Original Assignee
Xencor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/623,314 external-priority patent/US10787518B2/en
Application filed by Xencor Inc filed Critical Xencor Inc
Publication of MX2023006786A publication Critical patent/MX2023006786A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a anticuerpos inmunomoduladores, heterodiméricos y biespecíficos.
MX2023006786A 2016-08-30 2019-02-27 Anticuerpos inmunomoduladores biespecificos que se fijan a receptores coestimuladores y de puntos de control. MX2023006786A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662381239P 2016-08-30 2016-08-30
US201762456033P 2017-02-07 2017-02-07
US201762479723P 2017-03-31 2017-03-31
US15/623,314 US10787518B2 (en) 2016-06-14 2017-06-14 Bispecific checkpoint inhibitor antibodies

Publications (1)

Publication Number Publication Date
MX2023006786A true MX2023006786A (es) 2023-06-20

Family

ID=65632988

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023006786A MX2023006786A (es) 2016-08-30 2019-02-27 Anticuerpos inmunomoduladores biespecificos que se fijan a receptores coestimuladores y de puntos de control.

Country Status (9)

Country Link
EP (1) EP3507306A1 (es)
JP (2) JP7080219B2 (es)
KR (2) KR102575681B1 (es)
CN (1) CN110267990B (es)
AU (1) AU2017321625A1 (es)
CA (1) CA3035343A1 (es)
MX (1) MX2023006786A (es)
SG (1) SG11201901712YA (es)
ZA (1) ZA201901752B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015038884A2 (en) * 2013-09-13 2015-03-19 Genentech, Inc. Compositions and methods for detecting and quantifying host cell protein in cell lines and recombinant polypeptide products
WO2020092155A1 (en) * 2018-10-31 2020-05-07 Bioatla, Llc Anti-ctla4 antibodies, antibody fragments, their immunoconjugates and uses thereof
KR102170077B1 (ko) * 2018-05-21 2020-10-27 인하대학교 산학협력단 Prss14/st14의 자가분해 고리부분을 특이적으로 인식하는 단일클론항체 및 이의 용도
CN114195900B (zh) * 2020-09-17 2024-02-23 普米斯生物技术(珠海)有限公司 一种抗4-1bb/pd-l1双特异性抗体及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546543B2 (en) * 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
EP2638072A4 (en) * 2010-11-12 2014-05-07 Univ Rockefeller FUSION PROTEINS FOR HIV THERAPY
DK2943511T3 (da) * 2013-01-14 2019-10-21 Xencor Inc Nye heterodimeriske proteiner
AU2014232501C1 (en) * 2013-03-15 2021-04-22 Xencor, Inc. Heterodimeric proteins
CN106459182B (zh) 2013-12-30 2021-09-03 岸迈生物科技有限公司 串联fab免疫球蛋白及其用途
CN113929770A (zh) * 2014-11-21 2022-01-14 百时美施贵宝公司 包含修饰的重链恒定区的抗体
AU2015353416C1 (en) 2014-11-26 2022-01-27 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CD38
EP4071176A3 (en) * 2015-01-08 2022-12-14 BioNTech SE Agonistic tnf receptor binding agents
MA41414A (fr) * 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos

Also Published As

Publication number Publication date
CA3035343A1 (en) 2018-03-08
KR102575681B1 (ko) 2023-09-08
ZA201901752B (en) 2020-09-30
JP2019529368A (ja) 2019-10-17
AU2017321625A1 (en) 2019-04-04
CN110267990A (zh) 2019-09-20
RU2019109147A (ru) 2020-10-05
SG11201901712YA (en) 2019-03-28
JP2022111148A (ja) 2022-07-29
JP7080219B2 (ja) 2022-06-03
EP3507306A1 (en) 2019-07-10
KR20190044106A (ko) 2019-04-29
CN110267990B (zh) 2023-11-07
KR20230130174A (ko) 2023-09-11
RU2019109147A3 (es) 2021-01-22

Similar Documents

Publication Publication Date Title
MX2018015592A (es) Anticuerpos inhibidores de puntos de control biespecificos.
CY1124993T1 (el) Ετεροδιμερικα αντισωματα που δεσμευουν cd3 και cd20
AU2018366199A1 (en) Bispecific and monospecific antibodies using novel anti-PD-1 sequences
PH12017502019A1 (en) Heterodimeric antibodies that bind cd3 and tumor antigens
CY1123236T1 (el) Αντισωματα διπλης εξειδικευσης που δεσμευονται με cd38 και cd3
PH12017500982A1 (en) Heterodimeric antibodies that bind cd3 and cd38
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
MX2020009649A (es) Anticuerpos monoclonales contra bcma.
SG10201901057UA (en) Anti-pd-l1 antibodies
MX2018008369A (es) Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos.
MX2015013901A (es) Anticuerpos anti-il-4 y anticuerpos biespecificos y sus usos.
PE20210648A1 (es) Anticuerpos anti-cd3 y metodos de uso
MX2017007491A (es) Anticuerpos del receptor de la barrera hematoencefálica y métodos para su uso.
MX2023006786A (es) Anticuerpos inmunomoduladores biespecificos que se fijan a receptores coestimuladores y de puntos de control.
ZA201800804B (en) Novel anti-human gpvi antibodies and uses thereof
PH12019501605A1 (en) Glucagon receptor binding proteins and methods of use thereof
MX2019002349A (es) Anticuerpos inmunomoduladores biespecíficos que se fijan a receptores coestimuladores y de puntos de control.
MX2018009218A (es) Anticuerpos de cgrp y sus usos.